<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01116167</url>
  </required_header>
  <id_info>
    <org_study_id>you070316</org_study_id>
    <nct_id>NCT01116167</nct_id>
  </id_info>
  <brief_title>Polycystic Ovary Syndrome (PCOS): Effect Of Letrozole and Berberine</brief_title>
  <official_title>Letrozole and Berberine in Infertile PCOS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heilongjiang University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the People´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heilongjiang University of Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a heterogeneous disorder affecting almost4%-7% of the
      female population of reproductive age. Its heterogeneity is characterized by a wide spectrum
      of features, including ovulatory dysfunction and infertility, hyperandrogenism,
      hyperinsulinemia, insulin resistance (IR), and progression to type 2 diabetes.Since the Ming
      Dynasty in China,PCOS has been defined as &quot;phlegm and wetness&quot;infertility in traditional
      Chinese medicine ,namely &quot;metabolic infertility&quot;.Chinese herbs have been used to treat PCOS
      for thousands of years with good effects.Berberine has also been used for diabetic patients
      in traditional Chinese medicine for hundreds of years. Recent studies have reported its
      effects on hyperglycemia and dyslipidemia.The purpose of this study is to determine whether
      Letrozole combined with berberine are effective in the treatment of infertile PCOS patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live-birth rate</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ovulation rate</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate at around gestation 8-10 weeks</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple pregnancy rate</measure>
    <time_frame>Up to 1 year.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate: loss of an intrauterine pregnancy before 20 completed weeks of gestation</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other pregnancy complications such as early pregnancy loss, gestational diabetes mellitus, pregnancy-induced hypertension and birth of small-for-gestational-age (SGA) babies.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infant outcome</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolic profile: glucose and insulin concentrations, cholesterol, triglycerides, high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in hormonal profile: Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), total testosterone (T), Sex hormone-binding globulin (SHBG) and Dehydroepiandrosterone sulfate (DHEAS)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect.</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Letrozole -Berberine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Berberine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole -Berberine</intervention_name>
    <description>Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine
1.5g daily for 6 month.</description>
    <arm_group_label>Letrozole -Berberine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine Placebo
5 tablet tds for 6 months</description>
    <arm_group_label>Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Berberine</intervention_name>
    <description>Berberine
1.5g daily for 6 month.
Letrozole placebo
1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6.</description>
    <arm_group_label>Berberine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese women

          -  Age between 20 and 40 years.

          -  Confirmed diagnosis of PCOS according to the Rotterdam 2003 criteria (2 out of 3):

               1. Oligo- or anovulation

               2. Clinical and/or biochemical signs of hyperandrogenism

               3. Polycystic ovaries and exclusion of other etiologies (congenital adrenal
                  hyperplasia, androgen-secreting tumors, Cushing's syndrome)

          -  At least one patent tube and normal uterine cavity shown by hysterosalpingogram,
             HyCoSi or diagnostic laparoscopy within three years.

          -  Sperm concentration 20×106/mL and progressive motility (grades a and b) ≥50%.

        Exclusion Criteria:

          -  Use of hormonal drugs or other medications including Chinese herbal prescriptions in
             the past 3 months.

          -  Patients with known sever organ dysfunction or mental illness.

          -  Pregnancy, post-abortion or postpartum within the past 6 weeks.

          -  Breastfeeding within the last 6 months.

          -  Not willing to give written consent to the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lihui Hou, MD.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affliated Hospital,Heilongjiang University of Chinese Medicine .</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaoke Wu, MD.PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affliated Hospital,Heilongjiang University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yan Li, MD.PhD.</last_name>
    <email>liyantcm@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Anhui University of Chinese Medicine</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guangzhou Medical School First Affiliated Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hongxia Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daqing LongNa Hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <zip>163000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daqing Longnan hospital</name>
      <address>
        <city>Daqing</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Obstetrics and Gynecology,Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoke Wu, MD.PhD.</last_name>
      <phone>86-451-8213 0094</phone>
      <email>xiaokewu2002@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lihui Hou, MD.</last_name>
      <phone>86-451-8213 0094</phone>
      <email>houlihui2007@sina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lihui Hou, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoke Wu, MD.PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mudanjiang maternal and children hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>2nd Affiliated Hospital of Henan University of Chinese Medicine</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Hunan University of Chinese</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SuqianMaternal and Child Health Hospital</name>
      <address>
        <city>Suqian</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Hospital, Jiangxi college of Chinese Medicine</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dalian Maternal and Child Health Hospital</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanxi Hospital of Chinese Medicine</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Tianjin University of Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital, Tianjin University of Chinese Medicine</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zhejiang province hospital of integrated traditional and western medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Heilongjiang University of Chinese Medicine</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2010</study_first_submitted>
  <study_first_submitted_qc>May 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2010</study_first_posted>
  <last_update_submitted>May 17, 2013</last_update_submitted>
  <last_update_submitted_qc>May 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heilongjiang University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Xiaoke Wu</investigator_full_name>
    <investigator_title>Professor and Department Chairman of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

